Phase 3, 2-part, multicenter, open-label study of encorafenib (enco)+ binimetinib (bini) vs vemurafenib (vemu) in patients with BRAF-mutant metastatic melanoma
Binimetinib;Encorafenib;Vemurafenib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase 3, 2-part, multicenter, open-label study of encorafenib (enco)+ binimetinib (bini) vs vemurafenib (vemu) in patients with BRAF-mutant metastatic melanoma ### Output: Binimetinib;Encorafenib;Vemurafenib